Merck puts a price on its SpringWorks takeover bid

Merck signs 20-year lease in Delaware following $30M state incentive

Why Should Delaware Care?Earlier this year, Delaware officials awarded a drug-making behemoth $30 million on the condition it expanded its presence in the state. It came even after Gov. Matt Meyer said he would focus the state’s economic development strategy on giving out smaller-dollar incentives to smaller companies.In February, Delaware enticed Merck & Co. with a $30 million taxpayer grant to expand its manufacturing operation in the state. A…

Merck puts a price on its SpringWorks takeover bid

Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share

Merck KGaA to buy cancer specialist SpringWorks

$3.9 billion deal boosts Merck’s pipeline as it faces patent expiries

Merck KGaA nears $3.5bn deal for SpringWorks - Pharmaceutical Technology

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per share.

Merck KGaA closes in on SpringWorks deal at $3.5B price point

Merck KGaA said Thursday that its late-stage discussions to buy the rare cancer biotech SpringWorks Therapeutics have landed on a likely price of $47 per share. That would put the value of the pending deal ...

The pharmaceutical company wants to strengthen its business with cancer medicines with a billion-dollar purchase. Talks with a US company are far away. With the deal, Merck would iron out its own weaknesses.